Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 3'-azido-3'-deoxythymidine (AZT) monophosphate: an inhibitor of exonucleolytic repair of AZT-terminated DNA.

Literature DB >> 8388206

3'-azido-3'-deoxythymidine (AZT) monophosphate: an inhibitor of exonucleolytic repair of AZT-terminated DNA.

J A Harrington¹, J E Reardon, T Spector.

Abstract

A 3'-exonuclease(s) that excised 3'-azido-3'-deoxythymidine (AZT) monophosphate (AZTMP) from the 3' terminus of DNA was partially purified from two human cell lines. AZTMP inhibited the hydrolysis of AZTMP-terminated single-stranded and double-stranded DNA substrates. Thus, high levels of AZTMP might inhibit the exonuclease and trigger the toxicity of AZT by impairing the repair of AZTMP-terminated DNA.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1993 PMID： 8388206 PMCID： PMC187815 DOI： 10.1128/AAC.37.4.918

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

24 in total

1. The phosphorylation of 3'-deoxy-3'-fluorothymidine and its incorporation into DNA in a cellfree system from tumor cells.

Authors: P Langen; G Kowollik; G Etzold; H Venner; H Reinert
Journal: Acta Biol Med Ger Date: 1972

2. Herpes simplex virus type I DNA polymerase. Kinetic properties of the associated 3'-5' exonuclease activity and its role in araAMP incorporation.

Authors: D Derse; Y C Cheng
Journal: J Biol Chem Date: 1981-08-25 Impact factor: 5.157

3. Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex.

Authors: R Yarchoan; R W Klecker; K J Weinhold; P D Markham; H K Lyerly; D T Durack; E Gelmann; S N Lehrman; R M Blum; D W Barry
Journal: Lancet Date: 1986-03-15 Impact factor: 79.321

4. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors: D D Richman; M A Fischl; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; M S Hirsch
Journal: N Engl J Med Date: 1987-07-23 Impact factor: 91.245

5. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors: M A Fischl; D D Richman; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; R T Schooley
Journal: N Engl J Med Date: 1987-07-23 Impact factor: 91.245

6. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors: F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal: Science Date: 1983-05-20 Impact factor: 47.728

7. The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3'-azido-2',3'-dideoxythymidine and 2',3'-dideoxycytidine are highly dependent on the cell species.

Authors: J Balzarini; R Pauwels; M Baba; P Herdewijn; E de Clercq; S Broder; D G Johns
Journal: Biochem Pharmacol Date: 1988-03-01 Impact factor: 5.858

8. Exonucleolytic proofreading enhances the fidelity of DNA synthesis by chick embryo DNA polymerase-gamma.

Authors: T A Kunkel; A Soni
Journal: J Biol Chem Date: 1988-03-25 Impact factor: 5.157

9. Long-term tolerance and efficacy of 3'-azidothymidine and 3'-fluorothymidine treatment of asymptomatic monkeys infected with simian immunodeficiency virus.

Authors: D Böttiger; L Ståhle; S L Li; B Oberg
Journal: Antimicrob Agents Chemother Date: 1992-08 Impact factor: 5.191

10. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.

Authors: M Popovic; M G Sarngadharan; E Read; R C Gallo
Journal: Science Date: 1984-05-04 Impact factor: 47.728

12 in total

Review 1. Antiviral therapy for human immunodeficiency virus infections.

Authors: E De Clercq
Journal: Clin Microbiol Rev Date: 1995-04 Impact factor: 26.132

Review 2. Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription.

Authors: E J Arts; M A Wainberg
Journal: Antimicrob Agents Chemother Date: 1996-03 Impact factor: 5.191

Review 3. Synthesis of nucleoside phosphate and phosphonate prodrugs.

Authors: Ugo Pradere; Ethel C Garnier-Amblard; Steven J Coats; Franck Amblard; Raymond F Schinazi
Journal: Chem Rev Date: 2014-08-21 Impact factor: 60.622

Review 4. Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection.

Authors: B N Stretcher
Journal: Clin Pharmacokinet Date: 1995-07 Impact factor: 6.447

Review 5. Systemic antifungal agents. Drug interactions of clinical significance.

Authors: E Albengres; H Le Louët; J P Tillement
Journal: Drug Saf Date: 1998-02 Impact factor: 5.606

Review 6. Pharmacokinetic individualisation of zidovudine therapy. Current state of pharmacokinetic-pharmacodynamic relationships.

Authors: R M Hoetelmans; D M Burger; P L Meenhorst; J H Beijnen
Journal: Clin Pharmacokinet Date: 1996-04 Impact factor: 6.447

7. Structural basis for efficient phosphorylation of 3'-azidothymidine monophosphate by Escherichia coli thymidylate kinase.

Authors: A Lavie; N Ostermann; R Brundiers; R S Goody; J Reinstein; M Konrad; I Schlichting
Journal: Proc Natl Acad Sci U S A Date: 1998-11-24 Impact factor: 11.205

8. Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus.

Authors: B N Stretcher; A J Pesce; P T Frame; D S Stein
Journal: Antimicrob Agents Chemother Date: 1994-07 Impact factor: 5.191

9. Inhibition of human immunodeficiency virus type 1 integrase by 3'-azido-3'-deoxythymidylate.

Authors: A Mazumder; D Cooney; R Agbaria; M Gupta; Y Pommier
Journal: Proc Natl Acad Sci U S A Date: 1994-06-21 Impact factor: 11.205

10. Synchronization of cells in the S phase of the cell cycle by 3'-azido-3'-deoxythymidine: implications for cell cytotoxicity.

Authors: B Chandrasekaran; T E Kute; D S Duch
Journal: Cancer Chemother Pharmacol Date: 1995 Impact factor: 3.333